Analytical evaluation of Radiometer ABL90 FLEX PLUS enzymatic creatinine assay by Salvagno, Gian Luca et al.
Page 1 of 5
© Journal of Laboratory and Precision Medicine. All rights reserved. J Lab Precis Med 2019;4:26 | http://dx.doi.org/10.21037/jlpm.2019.07.01
Introduction
Chronic kidney disease (CKD) has become a worldwide 
health issue and is associated with considerable clinical, 
social and economic consequences. According to recent 
statistics, the mean prevalence of CKD is approximately 
13.4% around the world, with a frequency of patients 
in stages 3–5 as high as 8.1%, thus accounting for 
approximately 624 mil l ion people suffering from 
some advanced forms of renal dysfunction around the 
world (1). Regarding acute kidney injury (AKI), recent 
epidemiological data suggests that this life-threatening 
disorder may complicate up to 16% of hospital admissions, 
resulting in a nearly 4-fold higher risk of in-hospital 
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Background: The diagnosis of kidney disease strongly relies on accurate and reproducible measurements 
of creatinine, even when performed with point of care testing (POCT) devices. Therefore, this study aimed 
at performing a comprehensive evaluation of the analytical performance of a creatinine enzymatic assay on 
the Radiometer ABL90 FLEX PLUS.
Methods: This analytical evaluation encompassed the assessment of intra-assay, inter-assay and total 
imprecision, along with linearity on routine lithium-heparin plasma samples. Method comparison was also 
carried out using results generated with Radiometer ABL90 FLEX PLUS in heparinized whole blood and 
those obtained in paired heparinized plasma with a reference enzymatic creatinine assay and a Jaffe method, 
both assayed on Roche Cobas c702.
Results: The intra-assay imprecision of Radiometer ABL90 FLEX PLUS creatinine enzymatic assay was 
between 0.33–1.26%, the inter-assay imprecision between 0.64–1.78%, thus yielding a total imprecision 
of 0.79–1.99%. The linearity of the assay was excellent (r=1.000; P<0.001) in a range of plasma creatinine 
concentrations between 47 and 445 μmol/L. An excellent correlation was found between creatinine measured 
on heparinized whole blood using Radiometer ABL90 FLEX PLUS enzymatic assay and plasma creatinine 
assayed on the same centrifuged samples using both Roche Cobas c702 creatinine enzymatic assay (r=0.99 
and r=0.98; both P<0.001). Compared to both Roche Cobas assays the percent bias was ≤1% and the 
agreement at chronic kidney disease (CKD) diagnostic thresholds was ≥94%. 
Conclusions: The results of this analytical evaluation confirm that Radiometer ABL90 FLEX PLUS 
creatinine enzymatic assay is at least as suitable as a conventional clinical chemistry enzymatic technique for 
routine and urgent diagnosis of kidney diseases.
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mortality (2). This concerning epidemiologic information 
highlights the pivotal importance of an early diagnosis of 
both CKD and AKI, which would allow more timely and 
appropriate patient management, so reversing the otherwise 
unfavourable clinical trend which characterizes acute or 
chronic renal failure.
The diagnosis of both CKD and AKI strongly relies on 
laboratory diagnostics (3-5). More specifically, the Kidney 
Disease Improving Global Outcomes (KDIGO) Update 
Work Group currently recommends that CKD shall be 
diagnosed and classified according to glomerular filtration 
rate (GFR) categories (6). More specifically, stages (from 1 
to 5) are defined according to GFR values of ≥90, 89–60, 
59–30, 29–15 and <15 mL/min/1.73 m2, respectively. A 
specific GFR estimating equation is then suggested for 
initial patient assessment, preferably the 2009 CKD-EPI 
(Chronic Kidney Disease Epidemiology Collaboration) 
creatinine-based formula, according to which creatinine 
shall be measured in serum or plasma using methods 
with traceable calibration to the international standard 
reference materials and minimum bias compared with 
isotope-dilution mass spectrometry (IDMS) reference 
methodology (i.e., by using enzymatic assays). As regards 
AKI, the KDIGO also recommends that this condition shall 
also be diagnosed and staged according to serum or plasma 
creatinine values (7). More specifically, a diagnosis of AKI 
can be made when serum or plasma creatinine increases by 
≥26.5 μmol/L within 48 hours or by 1.5-fold during the 
past 7 days. AKI stages are then also defined according to 
creatinine variation, whereby an increase between 1.5–1.9 
fold or ≥26.5 µmol/L than the baseline defines stage 1, an 
increase between 2.0–2.9 times than the baseline defines 
stage 2, whereas an increase >3 fold or ≥353.6 μmol/L than 
the baseline characterizes stage 3, respectively.
As previously discussed, diagnosing and staging both 
CKD and AKI strongly rely on accurate and reproducible 
measurements of serum creatinine. Although the many 
advantages that have been made in central laboratory 
assessment of serum creatinine have now allowed to 
reach a satisfactory degree of accuracy and precision in 
this measurement, quantification of creatinine with point 
of care testing (POCT) devices remains problematic, as 
recently highlighted by Bargnoux et al. (8). In particular, 
analytical performance goals are still lacking for POCT 
devices, whilst it may be preferable that their analytical 
performance would be the same as that of clinical chemistry 
analyzers. This is an obvious consequence of evidence that 
the clinical decision making for patients with either CKD 
or AKI is now virtually identical regardless of whether 
serum or plasma creatinine is measured with laboratory 
instrumentation or with POCT devices.
Therefore, this work was aimed at carrying out a 
comprehensive evaluation of analytical performance of 
the recently introduced creatinine enzymatic assay on 
Radiometer ABL90 FLEX PLUS.
Methods
Instrument description
R a d i o m e t e r  A B L 9 0  F L E X  P L U S  ( R a d i o m e t e r, 
Copenaghen, Denmark) is a blood gas analyzer designed 
for POCT in busy clinical environments such as emergency 
departments (EDs) and intensive care units (ICUs), as well 
as for being used in physicians’ offices, where obtaining 
timely and accurate laboratory data may allow rapid 
diagnostics and more appropriate patient management. The 
analyzer can perform a range of critical care parameters, 
including blood gases, electrolytes, co-oximetry and 
metabolites, including (urea and) creatinine and automatic 
estimation of GFR (eGFR). As many as 19 parameters can 
be simultaneously analyzed, using 65 μL of blood, with 
first results available in 35 seconds. The instrument also 
enables easy operation by means of automatic sampler 
aspiration, disposable reagent cartridges, full compatibility 
with laboratory information system (LIS), integrated 
automated calibration and quality control usage. The 
measurement of creatinine on Radiometer ABL90 FLEX 
PLUS can be carried out in heparinized whole blood with 
an amperometric enzymatic two-sensor technology. The 
calibration of this method is traceable to IDMS.
Study protocol
The analytical evaluation of the enzymatic creatinine assay 
available on Radiometer ABL90 FLEX PLUS encompassed 
the assessment of both intra-assay, inter-assay and total 
imprecision, linearity (recovery) and method comparison 
with a reference enzymatic creatinine assay and a 
conventional Jaffe technique on a routine clinical chemistry 
analyzer.
Imprecision studies were carried out by preparing 3 pools 
of lithium-heparin plasma samples displaying low, normal 
and high creatinine values (Table 1), which were divided 
in different aliquots and tested (I) in 20 consecutive runs, 
during the same analytical session, for estimating intra-
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assay imprecision; and (II) in duplicate for 10 consecutive 
working days for calculating the inter-assay imprecision 
(in such case, aliquots were kept stored at −80 ℃ until 
thawing). The linearity of Radiometer ABL90 FLEX PLUS 
creatinine enzymatic assay was tested by serially diluting a 
pool of lithium-heparin plasma displaying a high creatinine 
value (i.e., 445 μmol/L), with a pool of lithium-heparin 
plasma displaying a low creatinine value (i.e., 47 μmol/L). 
Accuracy was finally estimated by comparing creatinine 
values in 130 consecutive routine heparinized blood 
samples (mean age, 66±16 years; 56 women and 74 men, 
with a range of creatinine concentrations between 47–445 
μmol/L) measured with Radiometer ABL90 FLEX PLUS 
creatinine enzymatic sensor , and in lithium-heparin plasma 
obtained after sample centrifugation (at 1,500 ×g for 10 min 
at room temperature), in which creatinine was assayed with 
Roche Cobas c702 enzymatic assay and Roche Cobas c702 
colorimetric Jaffe compensated assay (Roche Diagnostics, 
Basel, Switzerland). Both Roche creatinine methods are 
standardized against IDMS reference methodology. The 
intra-assay and inter-assay imprecision is 1.2–1.3% and 2.2–
2.5% for Roche Cobas c702 colorimetric Jaffe compensated 
assay, whilst it is 1.3–2.9% and 0.60–1.87% for Roche 
Cobas c702 enzymatic assay, respectively. 
Statistical analysis and Ethical Committee approval
Inter-assay, intra-assay and total imprecision were expressed 
as coefficient of variation (CV%). Total imprecision was 
estimated according to the equation of Krouwer and 
Rabinowitz (9). Linearity was calculated with Pearson’s 
correlation coefficient, whilst results of method comparison 
were analyzed with Spearman’s correlation and Bland and 
Altman plot analysis. The agreement at the five CKD 
diagnostic thresholds was calculated with Kappa statistics. 
The statistical analysis was carried out with Analyse-it 
(Analyse-it Software Ltd., Leeds, UK) and the statistical 
significance was set at P<0.05. The study was carried out 
employing pre-existing samples for which routine creatinine 
assessment was already requested, so that patients’ informed 
consent was unnecessary. Data obtained on Radiometer 
ABL90 FLEX PLUS were not reported and did not 
affect the clinical management of patients. The study was 
approved by the Ethical Committee of the University 
Hospital of Verona (SOPAV2; July 25, 2016).
Results
The results of intra-assay, inter-assay and total imprecision 
are shown in Table 1. Briefly, intra-assay imprecision was 
between 0.33–1.26%, inter-assay imprecision between 
0.64–1.78%, thus generating a total imprecision between 
0.79–1.99%. The linearity of the assay, as calculated with 
Pearson’s correlation, was excellent (r=1.000; P<0.001) in 
a range of plasma creatinine concentrations between 47 
and 445 μmol/L. The results of the method comparison 
are shown in Figure 1, which allowed calculating the bias 
between Radiometer ABL90 FLEX PLUS creatinine 
enzymatic assay and both the Roche Cobas c702 creatinine 
assays, as well as between the two Roche Cobas c702 
creatinine methods. Overall, an excellent correlation was 
found between creatinine measured on heparinized whole 
blood with Radiometer ABL90 FLEX PLUS enzymatic 
assay and plasma creatinine assayed on the same centrifuged 
samples using Roche Cobas c702 creatinine enzymatic 
assay (r=0.99; 95% CI, 0.98–0.99; P<0.001) and Roche 
Cobas c702 creatinine Jaffe assay (r=0.98; 95% CI, 0.98–
0.99; P<0.001). The correlation between the two Roche 
Cobas c702 creatinine methods was also excellent (r=0.99; 
95% CI, 0.99–0.99; P<0.001). The percent bias between 
Radiometer ABL90 FLEX PLUS creatinine enzymatic 
assay and Roche Cobas c702 creatinine enzymatic assay was 
−1.0% (95% CI, −1.9% to −0.1%), that with Roche Cobas 
c702 Jaffe assay was 0.6% (95% CI, −0.6% to 1.9%), whilst 
that between the two Roche techniques was −1.6% (95% 
CI, −2.5% to −0.8%). The agreement at the five CKD 
Table 1 Intra-assay, inter-assay and total imprecision of Radiometer ABL90 FLEX PLUS enzymatic creatinine assay
Pools
Intra-assay Inter-assay Total
Value CV (%) Value CV (%) CV (%)
Pool low (μmol/L) 50.7±0.5 0.90 51.6±0.9 1.78 1.99
Pool medium (μmol/L) 98.2±1.2 1.26 99.3±0.6 0.64 1.41
Pool high (μmol/L) 287.9±0.9 0.33 286.6±2.1 0.72 0.79
CV, coefficient of variation.
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diagnostic thresholds was 94% (kappa statistics, 0.90; 95% 
CI, 0.83–0.97; P<0.001) between Radiometer ABL90 FLEX 
PLUS creatinine enzymatic assay and Roche Cobas c702 
creatinine enzymatic assay, 95% (kappa statistics, 0.91; 95% 
CI, 0.85–0.98; P<0.001) between Radiometer ABL90 FLEX 
PLUS creatinine enzymatic assay and Roche Cobas c702 
Jaffe assay, and 95% (kappa statistics, 0.91; 95% CI, 0.85–
0.98; P<0.001) between the two Roche Cobas techniques.
Discussion
Due to an ongoing reorganization of laboratory services 
worldwide, strongly based on development of networks 
of clinical laboratories as well as on consolidation of some 
diagnostic areas and decentralization of others, the use 
of POCT devices has exponentially grown in the past 
decades (10,11). This instrumentation has hence become 
commonplace in short stay and critical care units for 
producing rapid results, as well as in peripheral laboratories 
or physician’s offices, where performance of a discrete and 
appropriate number of diagnostics tests may allow rapid 
decision making without the need to refer patients to large 
and frequently overcrowded facilities. Among the various 
tests that may be useful in these clinical settings, a rapid 
and accurate assessment of creatinine values would be 
valuable for screening CKD, for making an early diagnosis 
of AKI, as well as for assessing the risk of contrast-induced 
nephropathy and for short- or long-term monitoring 
of kidney function in the general population as well as 
in hemodialysed patients (8). Overall, creatinine values 
would enable taking many life-saving diagnostic decisions, 
provided that the accuracy of these measurements can be 
assured. 
The results of our imprecision studies revealed that 
the intra-assay, inter-assay and total imprecision of 
Radiometer ABL90 FLEX PLUS creatinine enzymatic 
assay are systematically lower than 2% (Table 1). These 
results are extremely valid considering that the analytical 
goals of serum creatinine measured with routine laboratory 
instrumentation has been set at <8% for diagnosing 
and staging CKD, and at <4% for diagnosing AKI, 
respectively (8). Even comparing these data with European 
Biological Variation Study (EuBIVAS), total imprecision of 
Radiometer ABL90 FLEX PLUS creatinine enzymatic assay 
remains lower than desirable imprecision (i.e., 2.2%), bias 
(i.e., 2.8%) and total error (i.e., 6.4%) for routine enzymatic 
techniques (12). Notably, the intra-assay imprecision of this 
POCT method was found to be even lower than that of 
many commercially available clinical chemistry techniques, 
including both Roche Cobas methods (13), and was much 
better than that of many other POCT assays available in the 
market (14). This would confirm that Radiometer ABL90 
FLEX PLUS creatinine enzymatic assay is highly suitable 
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Figure 1 Bland and Altman plots of plasma creatinine values 
measured with Radiometer ABL90 FLEX PLUS enzymatic 
creatinine assay, Roche Cobas c702 enzymatic assay and Roche 
Cobas c702 Jaffe assay. The straight blue lines are drawn at 
the mean bias, whilst the dotted blue lines designate the 95% 
confidence interval (95% CI).
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for longitudinal monitoring of blood creatinine. The 
linearity of the assay was also found to be excellent, between 
47–445 μmol/L (i.e., between 0.5–5.0 mg/dL), and thereby 
suitable for diagnosing kidney impairment throughout a 
wide measuring range, which would cover the vast majority 
of clinical samples. Finally, the results of correlation 
studies with a well-validated routine creatinine enzymatic 
assay confirm the accuracy of creatinine measurement on 
Radiometer ABL90 FLEX PLUS. The bias with both the 
Roche enzymatic and Jaffe methods was ≤1%, thus lower 
than the 2.2% desirable imprecision cut-off (12), whereas 
the agreement at CKD diagnostic thresholds was ≥94%.
Conclusions
The results of this comprehensive analytical evaluation of 
Radiometer ABL90 FLEX PLUS creatinine enzymatic 
assay confirm that this method is at least as suitable as 
conventional clinical chemistry enzymatic techniques for 
routine and urgent diagnosis of kidney diseases.
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